BLRX vs. CKPT, CALC, ELDN, IMRX, GANX, JAGX, RPHM, NBRV, AADI, and RMTI
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Checkpoint Therapeutics (CKPT), CalciMedica (CALC), Eledon Pharmaceuticals (ELDN), Immuneering (IMRX), Gain Therapeutics (GANX), Jaguar Health (JAGX), Reneo Pharmaceuticals (RPHM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), and Rockwell Medical (RMTI). These companies are all part of the "pharmaceutical preparations" industry.
BioLineRx (NASDAQ:BLRX) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.
BioLineRx presently has a consensus target price of $21.00, indicating a potential upside of 3,014.80%. Checkpoint Therapeutics has a consensus target price of $22.60, indicating a potential upside of 1,514.29%. Given BioLineRx's higher probable upside, research analysts clearly believe BioLineRx is more favorable than Checkpoint Therapeutics.
BioLineRx has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
BioLineRx received 333 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 73.32% of users gave BioLineRx an outperform vote while only 66.15% of users gave Checkpoint Therapeutics an outperform vote.
1.6% of BioLineRx shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Checkpoint Therapeutics had 7 more articles in the media than BioLineRx. MarketBeat recorded 8 mentions for Checkpoint Therapeutics and 1 mentions for BioLineRx. Checkpoint Therapeutics' average media sentiment score of 0.16 beat BioLineRx's score of -1.00 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media.
BioLineRx has a net margin of 0.00% compared to Checkpoint Therapeutics' net margin of -50,336.89%. Checkpoint Therapeutics' return on equity of 0.00% beat BioLineRx's return on equity.
Checkpoint Therapeutics has lower revenue, but higher earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Checkpoint Therapeutics beats BioLineRx on 9 of the 17 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
